Press Releases

SAN ANTONIO, TEXAS — August 21, 2007 – Seno Medical Instruments, Inc., a company engaged in the development of medical devices announced a $2 million dollar award from the Texas Emerging Technology Fund (TETF). This funding will allow the company to further develop its life saving technology for cancer imaging and detection and move it closer to the global marketplace.

Texas Secretary of State Phil Wilson and Seno Medical Instruments, Inc. CEO Janet Campbell announced the Fund’s investment during a joint press conference at the world renowned Cancer Therapy and Research Center in San Antonio. The patented functional imaging technology will be commercialized to produce real-time color images which differentiate benign and malignant tumors, for all solid tumors, such as in breast cancer. Seno’s intent is to provide the most advanced high quality products for cancer screening, diagnosis and therapeutic treatment that are more humane than existing technologies.

“I am pleased that the state of Texas and its elected leadership recognize and support Seno’s technology, and our effort to create better tools for the detection and treatment of breast cancer. On behalf of my management team, we are grateful for the support we’ve received from our investors and organizations, not only in our hometown of San Antonio, but across Texas and the nation,” said Campbell.

The TETF is a $200 million program created by the Texas Legislature in 2005. A 17-member advisory committee of high-tech leaders, entrepreneurs and research experts reviews potential TETF projects and recommends funding for projects to the Governor, Lieutenant Governor and Speaker of the House. To date, the TETF has allocated $94.1 million in grant funds to Texas companies and universities across the state.

“Technological innovation is the lifeblood of today’s economy,” said Texas Governor Rick Perry. “Texas is making an important investment, literally, in the foundation of our future. By supporting advancing technology projects, such as breast cancer diagnostic devices, we are making a difference in a wide variety of products and services that enhance the quality of lives here today, and in the future.”
Seno Medical has selected the Cancer Therapy and Research Center and the University of Texas Health Science Center at San Antonio to conduct initial clinical studies.

SAN ANTONIO, TEXAS—July 13, 2007—Seno Medical Instruments, Inc., a San Antonio company engaged in the development of medical devices announces the appointment of Lester Crawford, Ph.D., D.V.M. to its Scientific Advisory Committee. Dr. Crawford, widely known for his experience as Deputy Commissioner and Commissioner at the Food and Drug Administration between 2002 and 2005, joins a prestigious group of professionals dedicated to the early detection of cancer.

Seno Medical Instruments, Inc. was formed in 2005 to commercialize a new modality in cancer screening and diagnosis: laser opto-acoustic imaging. To further the development of this potentially life-saving technology, the company is assembling a team of experts in the field of breast cancer detection, product application and protocol design. Dr. Crawford joins Robert L. Kramer, M.D., founding member of the Susan G. Komen Advisory Board and Charles Coltman, M.D., President Emeritus of San Antonio’s Cancer Therapy and Research Center on the committee. Also on Seno Medical’s Scientific Advisory Committee is John W. Holaday, Ph.D., formerly listed among the 500 most cited scientists in the world by the Science Citation Index.

“We are delighted that Dr. Crawford has agreed to join our Scientific Advisory Committee. As a recognized leader of a national organization such as the FDA, we are confident he will bring a wealth of knowledge and experience to the committee and to the company,” said Janet Campbell, Seno Medical CEO.

Dr. Crawford has played major roles in mandatory nutrition labeling, the formation of the World Trade Organization and the control of chemical and microbiological contaminants of food. He has been an advisor to the World Health Organization of the United Nations for much of his career. Previously Chair of Department of Physiology-Pharmacology at the University of Georgia, Dr. Crawford has also been Administrator of the Food Safety and Inspection Service (USDA) and Director of the Center for Food and Nutrition Policy from 1997 to 2002, first at Georgetown University and at Virginia Tech, where it moved in 2001. He is a member of the National Academy of Sciences Institute of Medicine, a Fellow of the Royal Society of Medicine (UK) and a Fellow of the International Society of Food Science and Technology.

SAN ANTONIO, TEXAS—June 12, 2007—Seno Medical Instruments, Inc., a San Antonio company engaged in the development of medical devices announces the selection of John Holaday, PhD to its Scientific Advisory Committee. Dr. Holaday, formerly listed among the 500 most cited scientists in the world by the Science Citation Index, will be instrumental in Seno Medical’s efforts to bring its patented breast cancer diagnostic technology to the global marketplace.

Seno Medical Instruments, Inc. was formed in 2005 to commercialize a new modality in cancer screening and diagnosis: opto-acoustic imaging. To further the development of this potentially life-saving technology, the corporation is assembling a team of experts in the field of breast cancer detection, product application and protocol design.

“I am excited and honored that Dr. Holaday has decided to join our team,” said Janet Campbell, Seno Medical CEO. “Dr. Holaday brings a depth of knowledge in patents, strategic partnering and running successful medical companies. His expertise in science and the medical field will be invaluable to us.”

Dr. Holaday understands that despite the advances in treating breast cancer, the best way to manage the disease and to save lives is early detection. “Seno’s opto-acoustic technology creates a new diagnosis window. The ability to identify malignant tissues from the non-malignant based on differences in metabolic demand represents a breakthrough technology for the diagnosis of breast cancer with potential applicability to other forms of cancer,” said Dr. Holaday.

Dr. Holaday is currently CEO of QRxPharma, a newly listed specialty pharmaceutical company specializing in pain and CNS diseases (QRX, ASX). Dr. Holaday, a veteran life-science entrepreneur, built five public and private biopharmaceutical companies over the past 19 years and raised more than $360M in capital. As Chairman of the Maryland Bioscience Alliance (2000–2004), Dr. Holaday oversaw the largest biotechnology membership-based organization in the State. Dr. Holaday founded EntreMed, (ENMD, NASDAQ) in 1992 and served as its Chairman, President and CEO until his retirement in 2003 and was the co-founder, director, Scientific Director and SVP of Medicis Pharmaceutical Corporation (MRX, NYSE). He was the founder and Chief of the Neuropharmacology Branch at the Walter Reed Army Institute of Research for 21 years. Dr. Holaday is a graduate of the University of California, San Francisco School of Medicine with a PhD in neuropharmacology.

Dr. Holaday has received numerous honors and awards, including induction into Ernst and Young’s Entrepreneur of the Year 2006 Hall of Fame. He holds over 30 U.S. and foreign patents, has published more than 200 scientific articles and reviews, and edited five books.

SAN ANTONIO, TEXAS—May 29, 2007—Seno Medical Instruments, Inc., a San Antonio medical device company, announces its participation in the In3 Medical Device Summit taking place June 3–5. Seno Medical Instruments CEO, Janet Campbell, will present the company’s patented laser opto-acoustic medical imaging technology to attendees. Attendees will include some of the biggest dealmakers in the medical device industry, including members of the healthcare investment community.

Investors and fellow medical device executives will hear about Seno’s platform technology, which combines light and sound to produce high contrast images for cancer detection and treatment. This technology has a multitude of potential cancer applications which include breast, ovarian, prostate, colorectal, bladder and melanoma cancers. This innovative platform technology also has potential non-cancer applications in the areas of cardiovascular, inflammatory disease and stroke.

“We are excited to present our technology at this summit, known as the largest strategic partnership and investment meeting for medical technology executives. This summit is the most important venue of its kind for previewing cutting-edge emerging medical technology companies,” said Campbell, one of the first female CEO’s in the breast cancer imaging industry.

Seno’s initial imaging device for cancer researchers is expected to be released in the first quarter of 2008, with its breast cancer diagnostic to follow. The first clinical applications, breast cancer diagnosis and screening, will target a market estimated to be $5.9B (North America only).

SAN ANTONIO, TEXAS—April 18, 2007—Seno Medical Instruments, Inc., a San Antonio company engaged in the development of medical devices announces the election of J. Arturo Bonilla, M.D to its Board of Directors. Dr. Bonilla, a San Antonio surgeon well known for founding the Microtia-Congenital Ear Institute, will lend his business leadership skills to advance Seno Medical’s patented breast cancer diagnostic technology.

Seno Medical Instruments, Inc. was formed in 2005 to commercialize a new modality in cancer screening and diagnosis; opto-acoustic imaging. To further the development of this potentially life-saving technology, the corporation is assembling a team of experts in the field of breast cancer detection, product application and protocol design.

“Dr. Bonilla has been instrumental in securing support for this technology from esteemed members of the greater San Antonio medical community. As an entrepreneur with a successful record of investing, Dr. Bonilla proves to be an invaluable resource to Seno as we launch our innovative cancer diagnostic tools to market,” said Janet Campbell, Seno Medical CEO. “I feel very fortunate that Dr. Bonilla has agreed to join our Board of Directors.”

Dr. Bonilla says he is impressed by the company’s leadership and is encouraged by his fellow physicians” reactions to the technology. “When I saw the support from worldwide leading experts in medicine, especially radiology and oncology, I knew that we had something very special here,” said Bonilla. “The experience and integrity of this company and the hard work of all its staff has left me with no doubt this breakthrough technology will soon be commonplace. This in turn will save many lives.“

Dr. Bonilla is a pediatric ear, nose and throat surgeon based in San Antonio. Dr. Bonilla was also co-owner of the Pediatric Ear, Nose & Throat Institute of South Texas, and is one of only four such surgeons in South Texas. In addition to being the founder of the Microtia-Congenital Ear Institute, he has been featured in numerous media reports for his work in correcting birth defects of the ear. He has developed one of the largest individual ear reconstructive practices in the world. He is the co-founder and president of the Skin Concepts Laser Centers, a cosmetic hair and skin treatment center. Dr. Bonilla is also an investor and was a past member of the governing board of the Methodist Ambulatory Surgery Center at Stone Oak in San Antonio. He is also an investor and governing board member of the Physicians Ambulatory Surgery Centers, one of the largest physician-owned ambulatory surgery centers in the country. He is also a past member of the Medical School Interview Committee at The University of Texas Health Science Center at San Antonio.

Dr. Bonilla is a graduate of St. Mary’s University in San Antonio and received his medical degree from the University of Texas Health Science Center at Houston. He completed his general surgery residency at Methodist Hospital in Dallas and his residency in otolaryngology at the State University of New York. He completed his pediatric ear, nose & throat surgery subspecialty training at the Children’s Hospital of Pittsburgh.

SAN ANTONIO, TEXAS—February 26, 2007—Seno Medical Instruments, Inc.,, a San Antonio company engaged in the development of medical devices announces the appointment of Robert I. Kramer, M.D., FAAP to Chairman of its Scientific Advisory Committee.

SENO MEDICAL INSTRUMENTS, INC. Nominates DR. ROBERT KRAMER TO HEAD SCIENTIFIC ADVISORY COMMITTEE

SAN ANTONIO, TEXAS — February 26, 2007 – Seno Medical Instruments, Inc., a San Antonio company engaged in the development of medical devices announces the appointment of Robert I. Kramer, M.D., FAAP to Chairman of its Scientific Advisory Committee. Dr. Kramer, founding member of the Susan G. Komen Advisory Board, is highly regarded for his work in the field of pediatrics and for his support of cancer research and treatment.

Seno Medical Instruments, Inc. was formed in 2005 to commercialize a new modality in cancer screening and diagnosis: opto-acoustic imaging. To further the development of this potentially life-saving technology, the corporation is assembling a team of experts in the field of breast cancer detection, product application and protocol design.

“Dr. Kramer has a deep commitment to the field of breast cancer. He has worked with many early stage companies focused on medical advancement. His extensive experience and knowledge in biotechnology and medical devices is invaluable to us,” said Janet Campbell, Seno Medical CEO. “I feel very fortunate that Dr. Kramer has agreed to assume this responsibility in leading the Advisory Committee.”

Dr. Kramer is a retired professor of pediatrics and pulmonology from UT Southwestern Medical Center in Dallas, Texas. He was the founding medical director of the Division of Pulmonology and Cystic Fibrosis Research Center at the Children’s Medical Center in Dallas. Following his retirement, he became Chairman of the Department of Pediatrics at Baylor University Medical Center. He was the national medical director of the healthcare consulting division of Coopers & Lybrand and in this capacity had his initial introduction to the business of the life science industry. Dr. Kramer is a member of the Board of Directors and Advisory Boards of several early-stage life science companies. He is a member of the External Advisory Committee of the Department of Biomedical Engineering at the University of Texas, Austin.

Dr. Kramer is a native of Rhode Island and a graduate of Tufts University Medical School with a pediatric residency completed at Yale University School of Medicine. He holds an Executive MBA from Harvard Business School.